Featured Research

from universities, journals, and other organizations

Fostamatinib shown to be safe but not effective in rheumatoid arthritis patients unresponsive to biologic agents

Date:
January 27, 2011
Source:
Wiley - Blackwell
Summary:
In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study, however, fostamatinib was not effective in this group of patients, although the drug did appear to be safe.

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study, however, fostamatinib was not effective in this group of patients, although the drug did appear to be safe.

Related Articles


Results of this phase II trial are published in the February issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Patients with RA experience inflammation, pain and swelling of their joints that often limits daily activities and can lead to permanent disability. The National Arthritis Data Workgroup estimates that 1.3 million (0.6%) of adults in the U.S. have RA, affecting two to three times as many women as men. While many RA patients are successfully treated with disease-modifying anti-rheumatic drugs (DMARDs), those with moderate to severe RA may find that newer biologically-based therapies that inhibit cytokine activity, block T cell stimulation, or modify B cell biology slow disease progression, especially when combined with methotrexate (MTX). However, there remains a subgroup of the RA patient population who do not respond to DMARDs or current biologic therapies.

The three-month double-blind, placebo-controlled trial of R788, led by Mark Genovese, M.D., from Stanford University, enrolled 219 patients with active RA who failed to respond to one or more biologic therapies (TNF inhibitor, anakinra, abatacept, or rituximab). Patients were randomly assigned in a 2:1 ratio to receive 100 mg of R788 or placebo, respectively. Efficacy and safety were evaluated over three months. Researchers evaluated changes in the disease activity score (DAS); inflammation and joint damage were assessed by MRI.

"Our findings did not find an overall difference in efficacy between the small molecule drug, R788, and placebo," noted Dr. Genovese. "However, the drug was well tolerated and clinical benefit was found in only a subset of RA patients." Results showed that the primary outcome, the ACR 201 response, as well as the ACR 50 and 70 responses, were not significantly different between the group receiving R788 and the placebo group. However, in patients who entered the trial with an elevated C-reactive protein (CRP) level, analysis suggested a meaningful difference in the ACR 20 responses between the R788 (42%) and placebo (26%) groups. Additionally MRI results demonstrated improvement in joint inflammation in those patients with the greatest disease activity.

Researchers found that the 100mg dosage of R788 was well tolerated, with the most common adverse effects being nausea and diarrhea. "We found that 100mg of R788 was a tolerable dose for chronic administration in RA," concluded Dr. Genovese. "Phase III trials of R788 need to replicate our findings and identify subpopulations most likely to respond to this novel therapy."

1 The American College of Rheumatology provides a set of criteria (ACR 20, ACR 50, ACR 70) to use in clinical trials for rheumatoid arthritis that report the percentage of study participants who achieve improvement in tender or swollen joint counts. Therefore, the ACR 20 means that a 20 percent improvement in tender or swollen joint counts was achieved.


Story Source:

The above story is based on materials provided by Wiley - Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mark C. Genovese, Arthur Kavanaugh, Michael E. Weinblatt, Charles Peterfy, Julie DiCarlo, Michael L. White, Maryann O-Brien, Elliott B. Grossbard, Daniel B. Magilavy. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis & Rheumatism, 2010; DOI: 10.1002/art.30114

Cite This Page:

Wiley - Blackwell. "Fostamatinib shown to be safe but not effective in rheumatoid arthritis patients unresponsive to biologic agents." ScienceDaily. ScienceDaily, 27 January 2011. <www.sciencedaily.com/releases/2011/01/110127090443.htm>.
Wiley - Blackwell. (2011, January 27). Fostamatinib shown to be safe but not effective in rheumatoid arthritis patients unresponsive to biologic agents. ScienceDaily. Retrieved February 27, 2015 from www.sciencedaily.com/releases/2011/01/110127090443.htm
Wiley - Blackwell. "Fostamatinib shown to be safe but not effective in rheumatoid arthritis patients unresponsive to biologic agents." ScienceDaily. www.sciencedaily.com/releases/2011/01/110127090443.htm (accessed February 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, February 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Cherries, Snap Peas and More Tasty Spring Produce

Cherries, Snap Peas and More Tasty Spring Produce

Buzz60 (Feb. 27, 2015) — From sweet cherries to sugar snap peas, spring is the peak season for some of the tastiest and healthiest produce. Krystin Goodwin (@Krystingoodwin) has the best seasonal fruits and veggies to spring in to good health! Video provided by Buzz60
Powered by NewsLook.com
New FDA-Approved Diabetes Medicine Might Save Drugmaker

New FDA-Approved Diabetes Medicine Might Save Drugmaker

Newsy (Feb. 26, 2015) — The U.S. Food and Drug Administration approved new diabetes drug Toujeo on Wednesday, a move that might save French drugmaker Sanofi&apos;s profits. Video provided by Newsy
Powered by NewsLook.com
The Best Foods to Battle Stress

The Best Foods to Battle Stress

Buzz60 (Feb. 26, 2015) — If you&apos;re dealing with anxiety, there are a few foods that can help. Krystin Goodwin (@krystingoodwin) has the best foods to tame stress. Video provided by Buzz60
Powered by NewsLook.com
The 5 Best Tips to Look Younger Now

The 5 Best Tips to Look Younger Now

Buzz60 (Feb. 26, 2015) — Life happens, and we all get older, but forget the pricey anti-aging products and plastic surgery. You can tweak your habits to turn back the hands of time. Krystin Goodwin (@krystingoodwin) has a few simple tips to help you look and feel younger. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins